Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein (a) levels

Kardiologiya

Volumn 51, Issue 5, 2011, Pages 9-16

  Safarova, M S ^a   Trukhacheva, E P ^a   Ezhov, M V ^a   Afanasieva, O I ^a   Afanasieva, M I ^a   Tripoten, M I ^a   Lyakishev, A A ^a   Pokrovsky, S N ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

CHD; CIMT; Lipoprotein(a); Nicotinic acid; Risk factors

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; LIPOPROTEIN A; NICOTINIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLE DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; BLOOD; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG COMBINATION; DRUG EFFECT; HUMAN; HYPERLIPOPROTEINEMIA; INTIMA; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATHEROSCLEROSIS; CAROTID ARTERIES; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIAS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIPOPROTEIN(A); MALE; MIDDLE AGED; NIACIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRROLES; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 80052384849     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fruchart J. C., Sacks F., Hermans M. P. et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102(10 Suppl):1K-34K.
2. Utermann G. Lipoprotein (a). In: Scriver C. R., Beaudet A. L., Sly W. S., Valle D. (eds). The metabolic and molecular bases of inherited disease. 8-th ed. New York: McGraw-Hill 2001:2753-2787.
3. Koschinsky M. L., Marcovina S. M. Structure-function relationships in apolipoprotein (a): insights into lipoprotein (a) assembly and pathogenicity. Curr Opin Lipidol 2004;15:167-174.
4. Kamstrup P. R., Tybjsrg-Hansen A., Steffensen R. et al. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 2009;301:2331-2339.
5. Erqou S., Kaptoge S., Perry P. L. et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
6. Clarke R. et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. N Engl J Med 2009;361:2518-2528.
7. Erqou S., Peden J. F., Hopewell J. C. et al. Apolipoprotein (a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58, 000 participants. J Am Coll Cardiol 2010;55:2160-2167.
8. Nordeslgaard B. G., Chapman M. J., Ray K. et al. Lipoprotein (a) as a cardiovascular risk factor current status. Eur Heart J 2010;31:2844-2853.
9. Chapman M. J., Redfern J. S., McGovern M. E., Glral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126:314-345.
10. Digby J. E., McNeill E., Dyar O. J. et al. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-land upregulation of adiponectin. Atherosclerosis 2010;209:89-95.
11. Ganji S. H., Qin S., Zhang L. et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75.
12. Kuvin J. T., Dave DM., Sliney K. A. et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743-745.
13. Brown S. L., Sobel B. E., Fujii S. Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. Circulation 1995;92:767-772.
14. Holvoet P., Collen D. Lipid lowering and enhancement of fibrinolysis with niacin. Circulation 1995;92:698-699.
15. Johansson J. O., Egberg N., Asplund-Carbon A., Carlson LA. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk 1997;4:165-171.
16. Tavinlharan S., Sivakumar M., Lim S. C., Sum C. F. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clin Chim Acta 2007;376:41-44.
17. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999;142:105-112.
18. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clinical Pharmacol 2010;24:19-28.
19. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-361.
20. Brown B. G., Zhao X., Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, the HDL-Atherosclerosis Treatment Study (HATS). N Engl J Med 2001;345:1583-1592.
21. Taylor A. J., Sullenberger L. E., Lee H. J. et al. Arterial Biology for the Investigation ofthe Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517.
22. Kamstrup P. R., Benn M., Tybjaerg-Hansen A., Nordeslgaard B. G. Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008;117:176-184.
23. Taylor A. J., Lee H. J., Sullenberger L. E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-2250.
24. Yu C.-M., Zhang Q., Lam L. et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007;93:933-939.
25. Daskalopoulou S. S., Delaney JA., Filion K. B. et al. Discontinuation of statin therapy following an acute myocardial infarction: a populationbased study. Eur Heart J 2008;29:2083-2091.
26. Loscalzo J., Weinfeld M., Fless G. M., Scanu A. M. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10:240-245.
27. Discepolo W., Wun T., Berglund L. Lipoprotein (a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb 2006;35:314-321.
28. Tsimikas S., Tsironis L. D., Tselepis A. D. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007;27:2094-2099.
29. Ozaki K., Kubo T., Imaki R. et al. The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia. J Atheroscler Thromb 2006;13:216-219.
30. Matthews P. G., Wahlqvisl M. L., Marks S. J. et al. Improvement in arterial stiffness during hypolipidaemic therapy is offset by weight gain. Int J Obes Relat Metab Disord 1993;17:579-583.